TABLE 1.

Reporting odds ratios for the risk of anti-NMDA receptor encephalitis in the WHO pharmacovigilance database VigiBase.

Drug (active ingredient)	“Anti-NMDA receptor encephalitis” cases with vaccine (n = 51)	Non “Anti-NMDA receptor encephalitis” cases with vaccine (n = 4,091,614)	ROR	95% CI	p-value
HPV Vaccine	8	116,283	32.89	[15.8–68.7]	<0.001
DTP-Polio vaccine	8	70,006	54.72	[26.2–114.3]	<0.001
Influenza vaccine	7	280,525	11.68	[5.3–25.5]	<0.001
Varicella zoster vaccine	5	193,141	11.78	[4.7–29.2]	<0.001
Pneumococcal vaccine	4	241,627	7.4	[2.7–20.3]	<0.001
HIB vaccine	4	89,544	20.08	[7.3–55.1]	<0.001
Covid-19 vaccine	4	2,881,218	0.57	[0.2–1.6]	0.262
Yellow fever vaccine	3	26,614	50.02	[15.7–159]	<0.001